Track Cassava Sciences, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Cassava Sciences, Inc. PX91.F · Stock Open Cassava Sciences, Inc. in new tab

0.7610 EUR
Add to portfolio
EPS
-0.77
P/B
0.70
ROE
-55.79
Beta
-0.70
Target Price
159.25 EUR
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
EPS-0.77
Book Value1.15
Price to Book0.70
% Insiders2.050%
Estimates
Forward P/E-1.82
Forward EPS-0.44
Target Mean Price159.25

DCF Valuation

Tweak assumptions to recompute fair value for Cassava Sciences, Inc. (PX91.F)
Currency: EUR
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Cassava Sciences, Inc. Logo Cassava Sciences, Inc. Analysis (PX91.F)

United States Health Care Official Website Stock

Is Cassava Sciences, Inc. a good investment? Cassava Sciences, Inc. (PX91.F) is currently trading at 0.7610 EUR. Market analysts have a consensus price target of 159.25 EUR. This suggests a potential upside from current levels.

Investor FAQ

Does Cassava Sciences, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Cassava Sciences, Inc.?

Cassava Sciences, Inc. is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.

Company Profile

Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.

Exchange Ticker
NMS (United States) SAVA
MEX (Mexico) SAVA.MX
NASDAQ FLNA
FRA (Germany) PX91.F
Trades
Dividend History paid per year (EUR)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
May 10, 2017 0.14
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion